SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

SANTA CRUZ BIOTECHNOLOGY, INC.

TAFA2 siRNA (m): sc-154057

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

TAFA2, also known as FAM19A2 (family with sequence similarity 19 chemokine (C-C motif)-like member A2), is a 131 amino acid cytoplasmic protein that belongs to the TAFA family. The TAFA family is composed of five highly homologous genes that encode small secreted proteins. These proteins contain conserved cysteine residues at fixed positions, and are distantly related to MIP-1α, a member of the CC-chemokine family. Predominantly expressed in specific regions of the brain, TAFA proteins are thought to function as brain-specific chemokines or neurokines that act as regulators of immune and nervous cells. The gene that encodes TAFA2 contains 484,512 bases and maps to human chromosome 12q14.1. Encoding over 1,100 genes, chromosome 12 comprises approximately 4.5% of the human genome. Chromosome 12 is associated with a variety of diseases and afflictions, including hypochondrogenesis, achondrogenesis, Kniest dysplasia, Noonan syndrome and trisomy 12p, which causes facial developmental defects and seizure disorders.

REFERENCES

1. Allen, T.L., Brothman, A.R., Carey, J.C. and Chance, P.F. 1996. Cytogenetic and molecular analysis in trisomy 12p. Am. J. Med. Genet. 63: 250-256.
2. Delgado Carrasco, J., Casanova Morcillo, A., Zabalza Alvillos, M. and Ayala Garces, A. 2001. Achondrogenesis type II-hypochondrogenesis: radiological features. Case report. An. Esp. Pediatr. 55: 553-557.
3. Yokoyama, T., Nakatani, S. and Murakami, A. 2003. A case of Kniest dysplasia with retinal detachment and the mutation analysis. Am. J. Ophthalmol. 136: 1186-1188.
4. Tom Tang, Y., Emtage, P., Funk, W.D., Hu, T., Arterburn, M., Park, E.E. and Rupp, F. 2004. TAFA: a novel secreted family with conserved cysteine residues and restricted expression in the brain. Genomics 83: 727-734.
5. Forzano, F., Lituania, M., Viassolo, A., Superti-Furga, V., Wildhardt, G., Zabel, B. and Faravelli, F. 2007. A familial case of achondrogenesis type II caused by a dominant COL2A1 mutation and "patchy" expression in the mosaic father. Am. J. Med. Genet. A 143A: 2815-2820.
6. Wainwright, H. and Beighton, P. 2008. Visceral manifestations of hypochondrogenesis. Virchows Arch. 453: 203-207.
7. Lo, F.S., Luo, J.D., Lee, Y.J., Shu, S.G., Kuo, M.T. and Chiou, C.C. 2009. High resolution melting analysis for mutation detection for PTPN11 gene: applications of this method for diagnosis of Noonan syndrome. Clin. Chim. Acta 409: 75-77.
8. Benussi, D.G., Costa, P., Zollino, M., Murdolo, M., Petix, V., Carrozzi, M. and Pecile, V. 2009. Trisomy 12p and monosomy 4p: phenotype-genotype correlation. Genet. Test. Mol. Biomarkers 13: 199-204.

CHROMOSOMAL LOCATION

Genetic locus: Fam19a2 (mouse) mapping to 10 D2.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

PRODUCT

TAFA2 siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 µM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see TAFA2 shRNA Plasmid (m): sc-154057-SH and TAFA2 shRNA (m) Lentiviral Particles: sc-154057-V as alternate gene silencing products.

For independent verification of TAFA2 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-154057A, sc-154057B and sc-154057C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 µl of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 µl of RNAse-free water makes a 10 µM solution in a 10 µM Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

TAFA2 siRNA (m) is recommended for the inhibition of TAFA2 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor TAFA2 gene expression knockdown using RT-PCR Primer: TAFA2 (m)-PR: sc-154057-PR (20 µl). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.